SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies.
about
Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humansRole of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learnedEmerging treatment options for myelofibrosis: focus on pacritinibClinical potential of pacritinib in the treatment of myelofibrosisGenetics of myeloproliferative neoplasmsThe evolving treatment paradigm in myelofibrosisNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewModulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode DependentRandom mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitorHistone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.Emerging drugs for myelofibrosis.Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis.Managing patients with myelofibrosis and low platelet counts.The development, safety and efficacy of pacritinib for the treatment of myelofibrosis.Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignanciesGenetic methylation and lymphoid malignancies: biomarkers of tumor progression and targeted therapy.Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphomaNovel targeted therapy for acute myeloid leukemia with a dual FLT3 and JAK2 inhibitorPacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia.The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML.Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.Investigational Janus kinase inhibitors.Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibitionIdentification of a Dual Inhibitor of Janus Kinase 2 (JAK2) and p70 Ribosomal S6 Kinase1 (S6K1) Pathways.Targeting epigenetic regulations in cancerA novel class of piperidones exhibit potent, selective and pro-apoptotic anti-leukemia properties.Novel and emerging therapies for the treatment of polycythemia veraJAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasmsTumor-selective cytotoxicity of a novel pentadiene analogue on human leukemia/ lymphoma cellsBET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets.Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?JAK2 inhibition for the treatment of hematologic and solid malignancies.Emerging targeted therapies in myelofibrosis.Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects.Macrocycles in new drug discovery.JAK2 inhibitors in the treatment of myeloproliferative neoplasms.Diffuse large B cell lymphoma: molecular targeted therapy.Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.
P2860
Q21133609-83F3F17E-4EBA-4358-B8F1-0A9982F16AA1Q26738514-8F9EE746-017E-497E-A2CA-98592E191757Q26745939-9F823526-D64A-4C59-846C-ED6608EAF2B5Q26796450-439F20BC-A91C-4457-A370-4D8216910496Q26823651-3B138F1A-904B-4DB2-A691-7A4063ED7D14Q27021968-B5D4134B-9B8B-4559-A88C-14AC727B5720Q27304386-B18AC51B-9126-4E77-96DE-84ECA7E5A4D7Q27681086-48C88370-D61C-45EB-A0DA-87871604FCC7Q28482297-2A280759-6D22-437D-A72F-4D127EE60E90Q30251920-398FDBB0-E1E0-4C1C-A864-0FE8DDBB2E15Q33404574-44A8D543-B3B7-4A95-BF72-9BD1CE030019Q33419762-ABCA41D2-56E4-429B-95A1-796D1DF1BADCQ33432406-95187B8A-FAD7-4D87-8BB0-DE93E32B87DCQ33435178-96396A61-5B95-412F-8A3A-E5BA99D38097Q33437478-5B65E558-5392-4C95-AFA1-783415D9C96FQ33913937-8FE544E0-3B0A-45DE-9107-3764DD4634D6Q34448586-850F5587-7A15-4FAE-BD57-C4E3D334EB84Q34634995-B00B7B69-552B-4A64-ADE7-E15D57C075AAQ34640779-93A174D1-DD24-4504-AD1A-FB647995A66AQ34640790-CF57E01C-9EF3-4CAA-84EC-A23F9521A232Q34642403-51D07372-CFA3-4EBE-B219-0C121A068BDCQ34648724-A91C106F-A99C-4FEF-BD4B-E8AC5D528300Q34648812-ED352A5B-8154-491C-979D-5E0A6368336DQ35760845-823443BD-63EF-4424-B72E-7FF70A37E762Q36092925-0D0DFA98-D6EF-4BAB-8B04-EEE36D5CF279Q36398751-FD3DC16F-C42E-4ADF-8CAF-8D75947FD705Q36954631-A2FC75FE-F00F-427C-9417-F6FB89F6E993Q37069633-8F9ACF07-8A9F-428C-8AD9-98C040B70642Q37168138-A1AF49DA-924F-4ACD-8CFA-9E6DADD87AA7Q37415621-27B0D7AB-3AAB-4DB3-A8B1-832389465A89Q37693266-871025D0-7559-4AB3-9454-68939B665209Q37976467-5D22EB0F-7775-4887-A11E-47E2D93BDB57Q37998574-993FB981-D370-4E20-9F12-AFE5CF42D58AQ38001733-179AC651-AF9A-40DD-BD75-F7A517C15D2FQ38025160-13032309-0F28-4FE6-B8CA-DB9B6E814F40Q38027835-572B7F34-D02A-47D8-8339-B68FD61F540FQ38031632-2C931F5A-B2D3-4910-AF48-2E12898D3174Q38044736-02AAFB37-6395-46EE-B686-981F774904CCQ38053983-94838E3F-0A50-4205-92DC-DF6DB3AC1FA9Q38100790-534FE42F-9405-45FD-A0AE-7C97AFB5FC3B
P2860
SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
SB1518, a novel macrocyclic py ...... oid and lymphoid malignancies.
@ast
SB1518, a novel macrocyclic py ...... oid and lymphoid malignancies.
@en
SB1518, a novel macrocyclic py ...... oid and lymphoid malignancies.
@nl
type
label
SB1518, a novel macrocyclic py ...... oid and lymphoid malignancies.
@ast
SB1518, a novel macrocyclic py ...... oid and lymphoid malignancies.
@en
SB1518, a novel macrocyclic py ...... oid and lymphoid malignancies.
@nl
prefLabel
SB1518, a novel macrocyclic py ...... oid and lymphoid malignancies.
@ast
SB1518, a novel macrocyclic py ...... oid and lymphoid malignancies.
@en
SB1518, a novel macrocyclic py ...... oid and lymphoid malignancies.
@nl
P2093
P2860
P356
P1433
P1476
SB1518, a novel macrocyclic py ...... loid and lymphoid malignancies
@en
P2093
A D William
B W Dymock
K Ethirajulu
P2860
P2888
P304
P356
10.1038/LEU.2011.148
P577
2011-06-21T00:00:00Z
P5875
P6179
1010673286